Byetta, Januvia, Onglyza, and Victoza Pancreatic Cancer Cases
FDA’s Concern Over Incretin Mimetics
In 2013, the FDA began evaluating new research suggesting an increased risk of pancreatitis and pre-cancerous cellular changes in type 2 diabetes patients treated with incretin mimetics. These findings have raised significant concerns about the safety of this drug class.
Incretin Mimetic Drugs and Associated Risks
The class of incretin mimetics includes several drugs like Byetta (exenatide), Victoza (liraglutide), and Januvia (sitagliptin). The FDA’s safety announcement highlighted the potential risks linked to these medications.
Legal Developments in Incretin Mimetic Litigation
A large number of cases involving Byetta, Victoza, and Januvia were initially consolidated and later dismissed. However, this dismissal was overturned by the Ninth Circuit Court of Appeals in 2017, reactivating the litigation with new cases being filed.
Seeking Legal Recourse for Pancreatic Cancer
Patients who developed pancreatic cancer after using drugs like Byetta, Victoza, or Januvia may be entitled to compensation. The recent legal developments have opened avenues for affected individuals to seek justice and compensation for their injuries.
For further details on the FDA’s safety announcement, you can read it here.
Contacting The Levensten Law Firm for Legal Support If you or a loved one has suffered from pancreatic cancer after using these drugs, The Levensten Law Firm offers legal guidance and support in filing a claim.